Checks aortic valve tissue for transthyretin amyloid deposits in aortic stenosis

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with degenerative aortic stenosis who are having their aortic valve replaced by surgery. It studies amyloid deposits in the removed valve.

Age

Over 18 years old (up to 99 years).

Sex

Men and women can join.

Disease stage

Degenerative aortic stenosis, treated with aortic valve replacement surgery.

Main reasons for not taking part

• Aortic stenosis that is not degenerative: bicuspid valve, rheumatic disease, aortic regurgitation
• People under a legal protection system for adults (guardianship, curatorship, etc.)
• Pregnant women

The registry criteria, word for word

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

• Are you between 18 and 99 years old?YesNo

What the trial wants to find out

Cardiac amyloidosis is a restrictive cardiomyopathy with a potentially severe prognosis that can be life-threatening. It is linked in the vast majority of cases to a light chain deposition of immunoglobulin or transthyretin. Although myocardial involvement is predominant, other locations are possible: the atrioventricular conduction system, coronary arteries and valve leaflets. In systematic histological analyzes, deposits of amyloidosis infiltrating the aortic valve have been reported with a frequency of up to 74% for degenerative RA. The nature of these deposits has never been established because the immunostaining carried out all remained negative, probably due to decalcification prior to cutting. Currently, these deposits are considered to be local degenerative phenomena without clinical repercussions. However, the use of bone scintigraphy has shown a high prevalence, between 14 and 16%, of ATTR cardiac amyloidosis in patients with severe RA. The diagnosis of ATTR amyloidosis has been proven histologically in a few patients. Sequencing of the TTR gene has shown that they are mainly wild forms. In fact, the prevalence of transthyretin mutations in our local cohort is 20%.

The group in the trial

• patients undergoing surgical valve replacement for degenerative aortic stenosisTreatment being tested

  Treatment: Proteomic analysis